PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Sunitinib

Drugs in development · updated 30 October 2026

Sunitinib: clinical trials and development status

Other names and codes: Sutent

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 19 July 2006

As of 30 October 2026 Sunitinib is in 36 active clinical trials (recruiting or ongoing, phases I–III) for 40 diseases. The most advanced phase is III.

36Active trials
IIIMost advanced phase
40Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Sunitinib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 40 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Renal cell carcinomaIII9NCT05043090
Gastrointestinal stromal tumorIII7NCT03673501
NeoplasmIII4NCT03768063
MetastasisIII3NCT05043090
CarcinomaIII2NCT05043090
Islet cell adenomaIII2NCT05477576
Kidney neoplasmIII2NCT03091192
Urologic NeoplasmsIII2NCT03091192
Carcinoid tumorIII1NCT05477576
Gastro-enteropancreatic neuroendocrine tumorIII1NCT05477576
Gastrointestinal neoplasmIII1NCT07218926
Kidney diseaseIII1NCT03091192
Neuroendocrine tumorIII1NCT05477576
Multiple myelomaII4NCT02465060
Hepatocellular carcinomaII2NCT02465060
LymphomaII2NCT02465060
Non-Hodgkin lymphomaII2NCT02693535
OsteosarcomaII2NCT07477457
Pancreatic neoplasmII2NCT02465060
Prostatic NeoplasmsII2NCT02465060
Bladder neoplasmII1NCT02465060
Breast neoplasmII1NCT02465060
Colonic neoplasmII1NCT02465060
Colorectal neoplasmII1NCT02465060
Endometrial neoplasmII1NCT02465060
Esophageal neoplasmII1NCT02465060
GliomaII1NCT02465060
Hematologic neoplasmII1NCT02465060
Lung neoplasmII1NCT02465060
MelanomaII1NCT02465060

Everything on Sunitinib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch